海角社区

• share
• favorite_border

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase鈥疘II BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

HOUSTON 鈥� The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

In an effort to improve public health and reduce cancer risk in East Texas, leaders in Beaumont are working with The University of Texas MD鈥疉nderson Cancer Center to launch Be Well鈩� Beaumont through a newly announced $10 million gift from ExxonMobil.

• share
• favorite_border

Smokers undergoing lung cancer screening may have the best chance of quitting if they receive integrated care, which includes medication and comprehensive counseling with tobacco treatment specialists, according to researchers at The University of Texas MD鈥疉nderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

MD Anderson and Myriad announced a five-year strategic collaboration to accelerate the clinical evaluation and development of Myriad's molecular residual disease assay.

• share
• favorite_border

Patients diagnosed with late-stage or metastatic breast cancer have a statistically significant increased risk of pre-diagnosis cardiovascular disease (CVD) compared to those with early-stage cancer at diagnosis, according to researchers from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, has received the 2025 Edith and Peter O鈥橠onnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST). The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer (SCLC), which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.

• share
• favorite_border

MD Anderson and AmMax Bio announced agreements to develop and advance AmMax's AMB-066 monoclonal antibody therapy for colorectal cancer with minimal residual disease.

• share
• favorite_border

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.

• share
• favorite_border

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) 鈥� a rare, aggressive hyperinflammatory condition 鈥� who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features upcoming oral presentations by MD Anderson researchers at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, providing new insights and advances in hematological malignancies and diseases. All ASH content from MD Anderson can be found at MDAnderson.org/ASH.

• share
• favorite_border

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today was awarded nearly $8 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of faculty recruitment as well as lung and colorectal cancer screening and early detection programs to address cancer incidence rates across Texas.

• share
• favorite_border

A new study from researchers at The University of Texas MD Anderson Cancer Center finds that, in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer. The findings question conventional thinking on the genetic origins of breast cancer, which could influence early cancer detection methods. The study, published today in Nature, discovered that at least 3% of normal cells from breast tissue in 49 healthy women contain a gain or loss of chromosomes, a condition known as aneuploidy, and that they expand and accumulate with age. This poses questions for our understanding of 鈥渘ormal鈥� tissues, according to principal investigator Nicholas Navin, Ph.D., chair of Systems Biology.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today honored Tiffany Richards, Ph.D., A.P.R.N., A.N.P.-B.C., A.O.C.N.P., with the 2024 Brown Foundation Award for Excellence in Oncology Nursing.